FOLH1 and neoplasm: In the present study, we did not distinguish between de novo (n = 3) and progressive (n = 9) disease, nor did we stratify by tumour grade, as our primary aim was to evaluate PSMA a potential target for RLT in patients with otherwise limited or no remaining treatment option, regardless of prior therapy or disease setting.